Antipsychotic News and Research RSS Feed - Antipsychotic News and Research

Antipsychotics are medicines used to treat the symptoms of mental disorders such as schizophrenia, depression, bipolar disorder (sometimes called manic-depressive illness), anxiety disorders, and attention deficit-hyperactivity disorder (ADHD). Sometimes medications are used with other treatments such as psychotherapy.
Brain scans may help predict patients' response to antipsychotic drug treatment

Brain scans may help predict patients' response to antipsychotic drug treatment

Investigators at The Feinstein Institute for Medical Research have discovered that brain scans can be used to predict patients' response to antipsychotic drug treatment. The findings are published online in the latest issue of The American Journal of Psychiatry. [More]
Medicaid could save billions as patents for several blockbuster antipsychotic medications expire

Medicaid could save billions as patents for several blockbuster antipsychotic medications expire

Medicaid is expected to save billions of dollars a year as patents for several blockbuster antipsychotic medications expire and use of generic versions of these drugs increases, according to a new study by researchers at the University of Maryland School of Medicine. These savings may provide relief from the high costs of these medications and allow policymakers to lift restrictions on patients' access, the researchers argue. [More]
15th Annual Geriatric Health Care Symposium now open for registration

15th Annual Geriatric Health Care Symposium now open for registration

Registration is now open for the 15th Annual Geriatric Health Care Symposium, "Maximizing Independence for Optimal Aging," presented by the University of Louisville Institute for Sustainable Health & Optimal Aging. [More]
Diagnosing psychiatric disorder may not be as important as prescribing effective treatment

Diagnosing psychiatric disorder may not be as important as prescribing effective treatment

Nailing the diagnosis of a psychiatric disorder may not be important in prescribing effective treatment, according to Mark Zimmerman, M.D., a clinical researcher at Rhode Island Hospital. His opinion editorial was published online today in the Journal of Clinical Psychiatry. [More]
Allergan announces U.S. availability of SAPHRIS 2.5 mg tablets for children with bipolar I disorder

Allergan announces U.S. availability of SAPHRIS 2.5 mg tablets for children with bipolar I disorder

Allergan plc today announced that SAPHRIS (asenapine) 2.5 mg sublingual (placed under the tongue) black-cherry flavored tablets are available in pharmacies throughout the U.S. In March 2015, the U.S. Food and Drug Administration approved SAPHRIS for the acute treatment of manic or mixed episodes associated with bipolar I disorder in pediatric patients (ages 10 – 17). [More]
Study identifies trends in use of antipsychotic medications in young people in the U.S.

Study identifies trends in use of antipsychotic medications in young people in the U.S.

Despite concerns that use of antipsychotic medications in treating young people has increased, use actually declined between 2006 and 2010 for children ages 12 and under, and increased for adolescents and young adults. [More]
Use of antipsychotic drugs more common in boys than girls, research shows

Use of antipsychotic drugs more common in boys than girls, research shows

Boys are more likely than girls to receive a prescription for antipsychotic medication regardless of age, researchers have found. [More]
FAU awarded $2.1 million to examine effectiveness of antipsychotic medication for schizophrenia

FAU awarded $2.1 million to examine effectiveness of antipsychotic medication for schizophrenia

Florida Atlantic University's Charles E. Schmidt College of Medicine was recently awarded a $2.1 million, two-year contract by Otsuka America Pharmaceutical Inc. to conduct a study to examine the effectiveness of an injectable long-acting antipsychotic medication for schizophrenia and its impact on 30-day hospital readmission rates. [More]
Long-acting injectable antipsychotic medication benefits people with schizophrenia

Long-acting injectable antipsychotic medication benefits people with schizophrenia

Schizophrenia, which affects 2 million to 3 million people in the U.S., causes hallucinations, delusions and disorganization. Left untreated, the disease can cause a significant loss in quality of life, including unemployment and estrangement from loved ones. But many people with schizophrenia can control the disorder and live without symptoms for several years if they consistently take prescribed antipsychotic medication, typically a daily pill. [More]
Alexza updates, amends ADASUVE (Staccato loxapine) commercial partnerships with Ferrer and Teva

Alexza updates, amends ADASUVE (Staccato loxapine) commercial partnerships with Ferrer and Teva

Alexza Pharmaceuticals, Inc. today announced that it has updated and amended its ADASUVE (Staccato loxapine) commercial partnerships with Grupo Ferrer Internacional, S.A. and Teva Pharmaceutical Industries Ltd. Ferrer is Alexza's commercial partner for ADASUVE in the European Union, Latin America, the Commonwealth of Independent States and other countries in Europe. [More]
New data shows psychotropic medication use among Medicaid-enrolled foster children in Pennsylvania

New data shows psychotropic medication use among Medicaid-enrolled foster children in Pennsylvania

Today, the Department of Human Services, in partnership with PolicyLab at The Children's Hospital of Philadelphia, released new data on psychotropic medication use among Medicaid-enrolled Pennsylvania children in foster care, as well as the state's action plan to address the findings. [More]
HQO report shows variations across Ontario's long-term care homes regarding antipsychotic drug use

HQO report shows variations across Ontario's long-term care homes regarding antipsychotic drug use

There are major differences across Ontario's long-term care homes in the percentage of residents who are being prescribed antipsychotic medications, according to Looking for Balance, a report from Health Quality Ontario, the provincial advisor on health care quality. [More]
Indivior reports top-line results from RBP-7000 phase 3 trial for treatment of schizophrenia

Indivior reports top-line results from RBP-7000 phase 3 trial for treatment of schizophrenia

Indivior PLC today announced top-line results from its phase 3 clinical trial of RBP-7000, an investigational drug in development for the treatment of schizophrenia. In this pivotal study, both doses of RBP-7000 tested, 90 mg and 120 mg administered once-monthly, met the primary endpoint with statistically and clinically significant reductions in the symptoms of acute schizophrenia over an 8-week treatment period. [More]
New study explores parent satisfaction with research study on treating severe childhood aggression

New study explores parent satisfaction with research study on treating severe childhood aggression

A new study of families participating in a clinical trial to treat children with severe physical aggression explored the factors affecting parent satisfaction with the research study. [More]
Antipsychotic drugs may elevate child's risk for weight gain, type II diabetes

Antipsychotic drugs may elevate child's risk for weight gain, type II diabetes

Today in JAMA Pediatrics, researchers from The Children's Hospital of Philadelphia's (CHOP) PolicyLab published the largest study to date documenting the significant risks to children's health associated with prescription antipsychotics, a powerful a class of medications used to treat mental and behavioral health disorders. [More]
Death risk is higher for dementia patients who take antipsychotic drugs, new study shows

Death risk is higher for dementia patients who take antipsychotic drugs, new study shows

Drugs aimed at quelling the behavior problems of dementia patients may also hasten their deaths more than previously realized, a new study finds. [More]
People with severe schizophrenia have major differences in brain networks

People with severe schizophrenia have major differences in brain networks

People with a severe form of schizophrenia have major differences in their brain networks compared to others with schizophrenia, bipolar disorder and healthy individuals, a new study from the Centre for Addiction and Mental Health shows. [More]
GeneSight test better predicts antidepressant outcomes for patients with depression

GeneSight test better predicts antidepressant outcomes for patients with depression

The combinatorial, multi-gene GeneSight test has been found to better predict antidepressant treatment outcomes for patients with depression, and their use of health care resources, than any of the individual genes that comprise the test, according to a peer-reviewed analysis by investigators from the Mayo Clinic and Assurex Health, and published online by The Pharmacogenomics Journal. [More]
Non-drug approaches work better in people with Alzheimer's disease, dementia

Non-drug approaches work better in people with Alzheimer's disease, dementia

Doctors write millions of prescriptions a year for drugs to calm the behavior of people with Alzheimer's disease and other types of dementia. But non-drug approaches actually work better, and carry far fewer risks, experts conclude in a new report. [More]

Study: 31 states implement new policies for 'atypical' prescribing of antipsychotics to children

With a concern about inappropriate prescribing of antipsychotic medications to children, 31 states have implemented prior authorization policies for atypical antipsychotic prescribing, mostly within the past 5 years, and with most states applying their policies to children younger than 7 years of age, according to a study in the March 3 issue of JAMA. [More]
Advertisement
Advertisement